Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NMTC2
MCID: THY102
MIFTS: 58

Thyroid Cancer, Nonmedullary, 2 (NMTC2)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

About this section

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 56
Follicular Thyroid Carcinoma 52 29 6 17 71
Thyroid Carcinoma, Follicular 56 74 52 13
Thyroid Cancer, Follicular 52 71
Nmtc2 56 73
Thyroid Carcinoma, Follicular, Somatic 56
Cancer, Thyroid, Nonmedullary, Type 2 39
Thyroid Cancer, Non-Medullary, 2 73
Thyroid Follicular Carcinoma 54
Thyroid Gland Adenocarcinoma 71
Follicular Thyroid Cancer 54
Ftc 52

Characteristics:

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
somatic mutations found in nras


HPO:

31
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 188470
OMIM Phenotypic Series 56 PS188550
MeSH 43 D013964
UMLS 71 C0206682 C1704228 C2931367
Sources

Summaries for Thyroid Cancer, Nonmedullary, 2

About this section
OMIM : 56 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to struma ovarii and nevus, epidermal. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Focal Adhesion and Aldosterone synthesis and secretion. The drugs Iodine and cadexomer iodine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are abnormality of metabolism/homeostasis and follicular thyroid carcinoma

UniProtKB/Swiss-Prot : 73 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 74 Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50... more...

Sources

Related Diseases for Thyroid Cancer, Nonmedullary, 2

About this section

Diseases in the Familial Nonmedullary Thyroid Carcinoma family:

Thyroid Cancer, Nonmedullary, 2 Thyroid Cancer, Nonmedullary, 1
Thyroid Cancer, Nonmedullary, 3 Thyroid Cancer, Nonmedullary, 4
Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 struma ovarii 30.3 TSHR TG BRAF
2 nevus, epidermal 30.3 PTEN NRAS HRAS
3 substernal goiter 30.1 TG CALCA
4 endemic goiter 30.0 TSHR TG CALCA
5 graves disease 1 29.9 TSHR THRB TG CALCA
6 plummer's disease 29.9 TSHR THRB TG
7 congenital hypothyroidism 29.8 TSHR TG PAX8
8 thyroid carcinoma, familial medullary 29.8 TG CALCA BRAF
9 malignant struma ovarii 29.7 TG LGALS3
10 nontoxic goiter 29.7 TSHR TG CALCA
11 papillary thyroid microcarcinoma 29.7 TSHR TG CALCA BRAF
12 graves' disease 29.6 TSHR THRB TG PAX8
13 adenoma 29.6 TSHR TG LGALS3 BRAF
14 multinodular goiter 29.6 TSHR TG PAX8 HRAS CALCA
15 hyperthyroidism 29.5 TSHR THRB TG CALCA
16 ovarian germ cell teratoma 29.5 TG LGALS3
17 thyroid carcinoma 29.3 TSHR TG PTEN LGALS3 HRAS CALCA
18 renal cell carcinoma, nonpapillary 29.2 PTEN PAX8 NRAS KDR HRAS BRAF
19 glioblastoma multiforme 29.0 PTEN PPARG NRAS KDR HRAS BRAF
20 thyroid gland medullary carcinoma 28.9 TG PAX8 KDR CALCA
21 thyroiditis 28.8 TSHR THRB TG HRAS CALCA BRAF
22 nodular goiter 28.8 TSHR TG LGALS3 HRAS CALCA BRAF
23 hypothyroidism, congenital, nongoitrous, 2 28.7 TSHR TG PAX8 LGALS3
24 differentiated thyroid carcinoma 28.6 TSHR TG PPARG PAX8 NRAS HRAS
25 goiter 28.6 TSHR THRB TG PAX8 LGALS3 HRAS
26 hashimoto thyroiditis 28.5 TSHR TG LGALS3 CALCA BRAF
27 thyroid gland follicular carcinoma 28.5 TSHR THRB TG PTEN PPARG PAX8
28 thyroid tumor 28.4 THRB TG PTEN NRAS LGALS3 HRAS
29 hypothyroidism 28.0 TSHR THRB TG PAX8 LGALS3 CALCA
30 papillary carcinoma 28.0 TSHR TG PPARG PAX8 LGALS3 CALCA
31 thyroid gland disease 27.5 TSHR THRB TG PPARG PAX8 LGALS3
32 thyroid gland anaplastic carcinoma 27.0 TSHR TG PTEN PPARG PAX8 NRAS
33 follicular adenoma 26.9 TSHR TG TFF3 PTEN PPARG PAX8
34 thyroid gland cancer 25.7 TSHR THRB TG PTEN PPARG PAX8
35 familial papillary or follicular thyroid carcinoma 12.6
36 tumoral calcinosis, hyperphosphatemic, familial, 1 11.8
37 thyroid carcinoma, hurthle cell 11.6
38 tumoral calcinosis, hyperphosphatemic, familial, 2 11.2
39 tumoral calcinosis, hyperphosphatemic, familial, 3 11.2
40 familial tumoral calcinosis 11.2
41 48,xyyy 10.5
42 thyroid cancer, nonmedullary, 1 10.5
43 melphalan allergy 10.5 NRAS BRAF
44 malignant anus melanoma 10.4 NRAS HRAS
45 malignant dermis tumor 10.4 NRAS HRAS
46 malignant skin fibrous histiocytoma 10.4 NRAS HRAS
47 spitz nevus 10.4 HRAS BRAF
48 benign struma ovarii 10.4 TG NRAS
49 vulvar melanoma 10.4 NRAS HRAS
50 central nervous system melanocytic neoplasm 10.4 NRAS HRAS

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2
Sources

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

About this section

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 follicular thyroid carcinoma 31 HP:0006731
3 non-medullary thyroid carcinoma 31 HP:0040198

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)

Clinical features from OMIM:

188470

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.89 HRAS
2 Decreased viability GR00055-A-2 9.89 HRAS
3 Decreased viability GR00221-A-1 9.89 HRAS KDR NRAS PPARG
4 Decreased viability GR00221-A-2 9.89 HRAS KDR PPARG
5 Decreased viability GR00221-A-3 9.89 HRAS KDR NRAS PPARG
6 Decreased viability GR00221-A-4 9.89 KDR PPARG
7 Decreased viability GR00249-S 9.89 KDR
8 Decreased viability GR00386-A-1 9.89 PPARG
9 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KDR NRAS PAX8 PPARG

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 BRAF HRAS KDR LGALS3 NRAS PAX8
2 homeostasis/metabolism MP:0005376 10.21 BRAF HRAS KDR LGALS3 NRAS PAX8
3 growth/size/body region MP:0005378 10.2 BRAF HRAS KDR LGALS3 NRAS PAX8
4 endocrine/exocrine gland MP:0005379 10.13 BRAF HRAS NRAS PAX8 PPARG PTEN
5 digestive/alimentary MP:0005381 10.1 BRAF HRAS LGALS3 NRAS PTEN TFF3
6 immune system MP:0005387 10.1 BRAF KDR LGALS3 NRAS PPARG PTEN
7 nervous system MP:0003631 9.96 BRAF HRAS KDR LGALS3 PAX8 PPARG
8 neoplasm MP:0002006 9.92 BRAF HRAS LGALS3 NRAS PPARG PTEN
9 limbs/digits/tail MP:0005371 9.91 BRAF NRAS PAX8 PTEN TG THRB
10 normal MP:0002873 9.76 BRAF HRAS KDR MINPP1 NRAS PAX8
11 skeleton MP:0005390 9.7 BRAF HRAS KDR LGALS3 NRAS PAX8
12 vision/eye MP:0005391 9.23 BRAF KDR NRAS PAX8 PPARG PTEN
Sources

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

About this section

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2 cadexomer iodine Phase 3
3 Hormone Antagonists Phase 3
4
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
5
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
6
Indinavir Approved Phase 2 150378-17-9 5362440
7
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
8
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
9
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
10
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
11
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
12
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
13
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
14
Lithium carbonate Approved Phase 2 554-13-2
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
17
Sodium citrate Approved, Investigational Phase 2 68-04-2
18
Tamoxifen Approved Phase 2 10540-29-1 2733526
19
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
20
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
21
Durvalumab Approved, Investigational Phase 2 1428935-60-7
22
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Lenvatinib Approved, Investigational Phase 2 417716-92-8
25
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
26
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
27
Trametinib Approved Phase 2 871700-17-3 11707110
28
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
29
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
31
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
32
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
33
Imetelstat Investigational Phase 2 868169-64-6
34 Molgramostim Investigational Phase 2 99283-10-0
35
Tremelimumab Investigational Phase 2 745013-59-6
36
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
37 Hypoglycemic Agents Phase 2
38 Cytochrome P-450 Enzyme Inhibitors Phase 2
39
protease inhibitors Phase 2
40 HIV Protease Inhibitors Phase 2
41 Cytochrome P-450 CYP3A Inhibitors Phase 2
42
Motesanib diphosphate Phase 2 850649-62-6 11450633
43 Angiogenesis Inhibitors Phase 2
44 Analgesics, Non-Narcotic Phase 2
45 Cyclooxygenase 2 Inhibitors Phase 2
46 Analgesics Phase 2
47 Cyclooxygenase Inhibitors Phase 2
48 Antirheumatic Agents Phase 2
49 Anti-Inflammatory Agents Phase 2
50 Anti-Inflammatory Agents, Non-Steroidal Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
3 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
4 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
5 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
6 A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
7 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
8 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
9 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
10 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
11 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
12 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
13 Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma Completed NCT00061906 Phase 2 celecoxib
14 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
15 The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
16 Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas Completed NCT00026533 Phase 2 thalidomide
17 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
19 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
20 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
21 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Active, not recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
22 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
23 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
24 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
25 AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug. Active, not recruiting NCT02034981 Phase 2 Crizotinib
26 A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas Suspended NCT02008019 Phase 2 Everolimus 2.5 mg/day;Everolimus 10 mg/day
27 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
28 Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
29 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
30 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
31 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
32 Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
33 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
34 Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions Completed NCT00001452
35 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
36 Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma Completed NCT01150318 Administration of 131 iodine
37 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
38 Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients Completed NCT02465424
39 Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer Recruiting NCT04031339
40 Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm Recruiting NCT03105648
41 interNational Anaplastic Thyroid Cancer Tissue Bank and Database (NATT). Recruiting NCT01774279
42 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Active, not recruiting NCT02862470
43 A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 Active, not recruiting NCT03488134
44 Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples Enrolling by invitation NCT02239575
45 Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies Not yet recruiting NCT04128631
46 Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study Not yet recruiting NCT03639662
47 Dose-Response in Radionuclide Therapy of Thyroid Cancer Terminated NCT00416949

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Sources

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

About this section

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Follicular Thyroid Carcinoma 29 HRAS MINPP1 NRAS SRGAP1
Sources

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

About this section

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

40
Thyroid, Bone, Lymph Node, Lung, Brain, Liver, Pituitary
Sources

Publications for Thyroid Cancer, Nonmedullary, 2

About this section

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 1302)
# Title Authors PMID Year
1
SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. 56 6
23539728 2013
2
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. 54 6
11297621 2001
3
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. 6
24006476 2014
4
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. 6
23392294 2013
5
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
6
Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. 56
20628519 2010
7
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. 56
20001717 2009
8
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 6
19855393 2009
9
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. 6
18633438 2009
10
A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. 46 61
16822819 2006
11
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
12
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
13
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. 6
12727991 2003
14
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
15
Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. 54 61
20056739 2010
16
Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. 61 54
19528408 2009
17
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. 61 54
18997818 2009
18
Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. 61 54
18474620 2008
19
G13-dependent activation of MAPK by thyrotropin. 54 61
18445595 2008
20
[Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma]. 61 54
18341829 2008
21
Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT. 61 54
18279026 2008
22
The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. 54 61
17653082 2008
23
The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. 61 54
18989374 2008
24
Molecular biology of thyroid cancer initiation. 54 61
18055323 2007
25
[Iodothyronine deiodinases expression in thyroid neoplasias]. 54 61
17891232 2007
26
The ultraviolet filter benzophenone 2 interferes with the thyroid hormone axis in rats and is a potent in vitro inhibitor of human recombinant thyroid peroxidase. 54 61
17379648 2007
27
Recurrent fusion oncogenes in carcinomas. 61 54
17425505 2006
28
Importance of thyroglobulin levels for diagnosis and monitoring of follicular thyroid carcinoma in an adolescent with severe iodine deficiency. 54 61
17128567 2006
29
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. 54 61
16314832 2006
30
The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. 61 54
16614712 2006
31
Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin. 54 61
16570574 2006
32
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. 61 54
16203990 2005
33
AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. 61 54
16002527 2005
34
Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. 61 54
16102579 2005
35
Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. 54 61
15943828 2005
36
Solitary metachronous metastasis to the thyroid from renal clear cell carcinoma 19 years after nephrectomy: report of a case. 61 54
15912297 2005
37
The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. 61 54
15487449 2004
38
Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. 54 61
14991244 2004
39
Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study. 61 54
15118274 2004
40
Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors. 54 61
15757202 2004
41
Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma. 54 61
14718282 2004
42
Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. 61 54
14713269 2003
43
Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. 54 61
12970322 2003
44
Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. 61 54
12776192 2003
45
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. 61 54
12629092 2003
46
Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. 61 54
12574186 2003
47
Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. 61 54
12225639 2002
48
Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. 61 54
11701669 2001
49
Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. 54 61
11580997 2001
50
nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. 61 54
11502841 2001
Sources

Variations for Thyroid Cancer, Nonmedullary, 2

About this section

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6 (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.8(PTEN):c.672del (p.Tyr225fs)deletion Pathogenic 560358 rs1564566774 10:89717647-89717647 10:87957890-87957890
2 MINPP1 NM_004897.5(MINPP1):c.122C>T (p.Ser41Leu)SNV Pathogenic 5021 rs119486096 10:89264794-89264794 10:87505037-87505037
3 MINPP1 NM_004897.5(MINPP1):c.809A>G (p.Gln270Arg)SNV Pathogenic 5022 rs104894171 10:89268264-89268264 10:87508507-87508507
4 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
5 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
6 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
7 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
8 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
9 SRGAP1 NM_020762.4(SRGAP1):c.447A>C (p.Gln149His)SNV Pathogenic 208456 rs781626187 12:64410750-64410750 12:64016970-64016970
10 SRGAP1 NM_020762.4(SRGAP1):c.823G>A (p.Ala275Thr)SNV Pathogenic 208457 rs797044990 12:64456718-64456718 12:64062938-64062938
11 HRAS NM_005343.4(HRAS):c.181C>A (p.Gln61Lys)SNV Pathogenic/Likely pathogenic 12601 rs28933406 11:533875-533875 11:533875-533875
12 SRGAP1 NM_020762.4(SRGAP1):c.1849C>T (p.Arg617Cys)SNV risk factor 208458 rs114817817 12:64502747-64502747 12:64108967-64108967
13 PTEN NM_000314.8(PTEN):c.882T>G (p.Ser294Arg)SNV Uncertain significance 127693 rs143335584 10:89720731-89720731 10:87960974-87960974
14 PTEN NM_000314.8(PTEN):c.892C>G (p.Gln298Glu)SNV Uncertain significance 127695 rs371387815 10:89720741-89720741 10:87960984-87960984
15 PTEN NM_000314.8(PTEN):c.235G>A (p.Ala79Thr)SNV Likely benign 41682 rs202004587 10:89690828-89690828 10:87931071-87931071
16 HRAS NM_005343.4(HRAS):c.520C>T (p.Pro174Ser)SNV Benign 40448 rs397517144 11:532686-532686 11:532686-532686

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

73
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

Sources

Expression for Thyroid Cancer, Nonmedullary, 2

About this section
Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.
Sources

Pathways for Thyroid Cancer, Nonmedullary, 2

About this section

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Focal Adhesion 36 1
Show member pathways
 12.79 PTEN NRAS KDR HRAS BRAF
2
Aldosterone synthesis and secretion 36
Show member pathways
 12.72 TSHR TG PAX8 NRAS HRAS BRAF
3
Endometrial cancer 36
Show member pathways
 12.66 PTEN PPARG PAX8 NRAS HRAS BRAF
4
Pathways in cancer 36
12.52 PTEN PPARG PAX8 NRAS HRAS BRAF
5
ErbB signaling pathway 36 1
Show member pathways
 12.49 PTEN NRAS KDR HRAS BRAF
6
VEGF Signaling 66
Show member pathways
 12.4 PTEN NRAS KDR HRAS
7
Oxytocin signaling pathway 36
Show member pathways
 12.39 NRAS HRAS CALCA BRAF
8
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.31 PTEN NRAS HRAS BRAF
9
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.27 PTEN NRAS KDR HRAS BRAF
10
Proteoglycans in cancer 36
12.2 NRAS KDR HRAS BRAF
11
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.18 PPARG NRAS HRAS BRAF
12
MAPK Signaling: Mitogens 64
Show member pathways
 12.09 PTEN NRAS KDR HRAS BRAF
13
mTOR Pathway 70
Show member pathways
 12.06 PPARG NRAS HRAS BRAF
14
Jak Stat Signaling Pathway 66
Show member pathways
 12.01 NRAS HRAS BRAF
15
FoxO signaling pathway 36
Show member pathways
 11.93 PTEN NRAS HRAS BRAF
16
Sphingolipid signaling pathway 36
11.91 PTEN NRAS HRAS
17
Serotonergic synapse 36
11.9 NRAS HRAS BRAF
18
DNA Damage Response (only ATM dependent) 1
11.89 PTEN NRAS HRAS
19
MAP Kinase Signaling 4
11.88 NRAS HRAS BRAF
20
Long-term potentiation 36
Show member pathways
 11.86 NRAS HRAS BRAF
21
Senescence and Autophagy in Cancer 1
11.84 PTEN HRAS BRAF
22
Bladder cancer 36 1
11.65 NRAS HRAS BRAF
23
Central carbon metabolism in cancer 36
11.62 PTEN NRAS HRAS
24
Glioblastoma Multiforme 63
11.6 PTEN NRAS HRAS BRAF
25
Negative regulation of MAPK pathway 65
Show member pathways
 11.58 NRAS HRAS BRAF
26
Long-term depression 36
11.53 NRAS HRAS BRAF
27
VEGF Pathway (Tocris) 60
Show member pathways
 11.38 NRAS KDR HRAS BRAF
28
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics 60
11.28 NRAS HRAS BRAF
29
BDNF-TrkB Signaling 1
11.15 NRAS HRAS BRAF
30
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.02 PTEN NRAS HRAS
31
Vemurafenib Pathway, Pharmacodynamics 60
10.89 NRAS KDR HRAS BRAF
32
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
10.85 TSHR PAX8 MIR197 HRAS BRAF
33
p38MAPK events 65
10.74 NRAS HRAS
34
Thyroxine (Thyroid Hormone) Production 1
10.35 TSHR TG
Sources

GO Terms for Thyroid Cancer, Nonmedullary, 2

About this section

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.88 THRB PPARG PAX8 LGALS3 KDR BRAF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 PTEN KDR HRAS BRAF
3 hormone-mediated signaling pathway GO:0009755 9.43 TSHR THRB PPARG
4 cellular response to nerve growth factor stimulus GO:1990090 9.33 PTEN CALCA BRAF
5 regulation of axon regeneration GO:0048679 9.32 PTEN BRAF
6 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 TSHR PAX8
7 thyroid gland development GO:0030878 8.92 THRB TG PAX8 BRAF

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.55 TSHR NRAS HRAS CALCA BRAF
2 transcription factor activity, direct ligand regulated sequence-specific DNA binding GO:0098531 9.26 THRB PPARG
3 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 PTEN MINPP1
4 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8
Sources

Sources for Thyroid Cancer, Nonmedullary, 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....